CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals, Inc. (Amex: JAV-News) announced today that its recent meeting with the USFDA and representatives of the US Department of Defense (DOD) provided guidance to complete the development of PMI-150, its proprietary formulation of ketamine for intranasal use. Based on this face-to-face meeting, and summary minutes received January 26, 2007, the Company intends to file a New Drug Application (NDA) for PMI-150 as an emergency analgesic for military and civilian use in 2008.
